-
Mashup Score: 15
PURPOSE Newer-generation tyrosine kinase inhibitors (TKIs) for non–small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have demonstrated high CNS activity. The optimal use of up-front stereotactic radiosurgery (SRS) for brain metastases (BM) in patients eligible for CNS-penetrant TKIs is controversial, and data to guide patient management are limited. MATERIALS AND METHODS Data on TKI-naïve patients with EGFR- and ALK-driven NSCLC with BM treated with CNS-penetrant TKIs with and without up-front SRS were retrospectively collected from seven academic centers in the United States. Time-to-CNS progression and overall survival (OS) were analyzed, with multivariable adjustment in Fine & Gray and Cox proportional hazards models for clinically relevant factors. RESULTS From 2013 to 2022, 317 patients were identified (200 TKI-only and 117 TKI + SRS). Two hundred fifty (79%) and 61 (19%) patients received osim
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 31
PURPOSE Paclitaxel, ifosfamide, and cisplatin (TIP) is an established salvage regimen for germ cell tumors (GCT) on the basis of a phase II trial, but efficacy on a large patient cohort including patients with unfavorable risk features and long-term outcomes has not been reported. Herein, we report updated treatment efficacy and long-term follow-up with TIP. PATIENTS AND METHODS Patients with GCT who received TIP after cisplatin-based chemotherapy were eligible. Favorable response (complete response or partial response with negative tumor markers), overall survival (OS) and progression-free survival (PFS) rates, relapse, and toxicity were determined. Disease was reclassified according to the International Prognostic Factor Study Group (IPFSG) score. RESULTS Of the 104 patients, 87 had favorable risk factors and 17 had at least one unfavorable factor by Memorial Sloan Kettering Cancer Center (MSKCC) criteria. Ten patients were treated for a second gonadal primary GCT. With a median foll
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Paclitaxel, Ifosfamide, & Cisplatin (TIP) show long-term efficacy as salvage chemotherapy for germ cell tumors— similar outcomes for favorable/unfavorable risk diseases. Eagerly awaiting the TIGER trial results! @JCO_ASCO #OncologyResearch #GermCellTumors https://t.co/sDKaupV2ul
-
-
Mashup Score: 36Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial - 4 month(s) ago
Zhou et al. evaluated neoadjuvant SHR-1701 with chemotherapy, followed by surgery or radiotherapy in treating unresectable stage III NSCLC in a phase 2 trial. The regimen demonstrated promising anti-tumor activity with an acceptable safety profile. Surgical conversion after neoadjuvant treatment was feasible and was associated with better survival outcomes.
Source: www.cell.comCategories: General Medicine News, Oncologists1Tweet-
📢 New promising strategy in treating unresectable stage III #NSCLC with neoadjuvant SHR-1701 + chemo, followed by surgery or radiotherapy. Surgical conversion post-treatment linked to better survival outcomes ✨#LungCancerResearch #Oncology 🩺https://t.co/Qb2XZ6n0Mo https://t.co/GEt5E7I6ZZ
-
-
Mashup Score: 18
Recent progress in adjuvant immunotherapy offers hope for improving disease-free survival in high-risk bladder cancer (BC) and renal cell carcinoma (RCC). This …
Source: journals.sagepub.comCategories: General Medicine News, Oncologists2Tweet-
Timely and nice review by @DrYukselUrun on emerging strategies in adjuvant immunotherapy for bladder cancer and renal cell carcinoma. What's the role of ctDNA in therapy selection? https://t.co/1PnZSUQvfC #Immunotherapy #BladderCancer #RenalCellCarcinoma #Oncology @SageClinMed https://t.co/rpc8S05NfO
-
-
Mashup Score: 6Giuseppe Banna: The Second International Urology Cancer Summit will take place in Portsmouth on September 27, 2024 - OncoDaily - 6 month(s) ago
Giuseppe Banna: The Second International Urology Cancer Summit will take place in Portsmouth on September 27, 2024 / Akash Maniam, Alison Tree, Ananya
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet-
RT @oncodaily: The Second @urologysummit will take place in Portsmouth on September 27, 2024 - @gbanna74 https://t.co/OyPzQkOxo1 #Cancer…
-
-
Mashup Score: 14Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas - 7 month(s) ago
Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas
Source: tlcr.amegroups.orgCategories: General Medicine News, Oncologists2Tweet-
Exciting new research from @UoPScience. High expression of the #DMD gene and Dp71 transcript linked to shorter survival in #mesothelioma. Promising step towards personalized medicine. https://t.co/g34rCSFhko @OncoAlert @OncoViews @oncodaily @CancerAlliance https://t.co/4qjGrHumN1
-
-
Mashup Score: 8The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma- A review of the literature - 9 month(s) ago
Paraneoplastic neurological syndromes (PNS) are rare neurological disorders arising from malignancy-triggered autoimmunity, yet their association with…
Source: www.sciencedirect.comCategories: General Medicine News, Oncologists2Tweet-
Delving into the link between Paraneoplastic Neurological Syndromes (PNS) and Urothelial Carcinoma 🧠🔬https://t.co/gjoEcqcpEj 📑 Rare yet significant connection, predominantly in elderly women w cerebellar syndromes Immunomodulation + tumor resection show promise. @ManiamAkash https://t.co/i7LpXTuHqi
-
-
Mashup Score: 1
Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC), Meet-URO score, ZEBRA Study (Meet-URO 9), Cabozantinib, vascular endothelial growth factor (VEGF) inhibitors, metastatic renal cell carcinoma treatment, ZEBRA/Meet-URO-9 study, nivolumab, ipilimumab, IMDC score.
Source: www.urotoday.comCategories: General Medicine News, Oncologists2Tweet-
https://t.co/OKulimDanG
-
-
Mashup Score: 0Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study - 9 month(s) ago
Scientific Reports – Instrumental activities of daily living in older patients with metastatic prostate cancer: results from the meet-URO network ADHERE prospective study
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet-
🌐 Importance:Understanding the impact of IADL and caregiver support is crucial for optimizing adherence to ARPIs in metastatic castrate-resistant PC patients aged ≥ 70. 🎯 📚 Read the full study: https://t.co/uEibiMELmm #ProstateCancer #GeriatricOncology #ClinicalResearch 👨⚕️
-
-
Mashup Score: 1Listen to what Monty Pal told at IUCS23 on first-line therapy for mRCC - 10 month(s) ago
Watch this videoclip from the Monty Pal presentation at #IUCS23 titled “How to choose first-line therapy for mRCC”
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet-
RT @urologysummit: Listen to @montypal discussing at #IUCS23 about treatment of #nccRCC #mRCC #renalcancer 👉 https://t.co/S4YCeGIq8h https:…
-
In view of TURBO-NSCLC study results, would you offer TKIs + SRS in EGFR/ALK+ve NSCLC patients? @OncoAlert @OncoViews @OncBrothers https://t.co/aM3fT4Ip3C #NSCLC #LungCancer #Oncology #TKI #SRS #EGFR #ALK #CancerResearch #TURBONSCStudy